Pneumococcal Vaccination in Children with Cancer

Te-Yu Hung

Research output: ThesisMaster's Thesis

22 Downloads (Pure)

Abstract

Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.
Original languageEnglish
QualificationMasters
Awarding Institution
  • The University of Western Australia
Award date28 Aug 2018
DOIs
Publication statusUnpublished - 2018

Fingerprint

Vaccination
Immunosuppressive Agents
Neoplasms
Conjugate Vaccines
Cohort Studies
Therapeutics
13-valent pneumococcal vaccine

Cite this

@phdthesis{16abf33da9ca46f78ab485d801b6f173,
title = "Pneumococcal Vaccination in Children with Cancer",
abstract = "Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.",
keywords = "Pneumococcal vaccination, lmmunogenicity, lmmunocompromised, Vaccine safety, Oncology, high risk population",
author = "Te-Yu Hung",
year = "2018",
doi = "10.26182/5bdba6076d002",
language = "English",
school = "The University of Western Australia",

}

Hung, T-Y 2018, 'Pneumococcal Vaccination in Children with Cancer', Masters, The University of Western Australia. https://doi.org/10.26182/5bdba6076d002

Pneumococcal Vaccination in Children with Cancer. / Hung, Te-Yu.

2018.

Research output: ThesisMaster's Thesis

TY - THES

T1 - Pneumococcal Vaccination in Children with Cancer

AU - Hung, Te-Yu

PY - 2018

Y1 - 2018

N2 - Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.

AB - Children with cancer receiving immunosuppressive therapy are vulnerable to severe pneumococcal disease (IPD). This thesis examines the role of the 13-valent pneumococcal conjugate vaccine (PCV13) in children undergoing (AIT) or recently completed immunosuppressive cancer therapy (CIT) to prevent and reduce IPD. A prospective, open-label cohort study included children with cancer given a dose of PCV13 demonstrated satisfactory immunogenic responses and low rate of serious adverse events. Our study design was suboptimal to evaluate vaccination and its role for preventing nasopharyngeal colonization.

KW - Pneumococcal vaccination

KW - lmmunogenicity

KW - lmmunocompromised

KW - Vaccine safety

KW - Oncology

KW - high risk population

U2 - 10.26182/5bdba6076d002

DO - 10.26182/5bdba6076d002

M3 - Master's Thesis

ER -